No abstract

Proliferative activity of lymphoma cells was tested by immunocytochemical staining with Ki-67 monoclonal antibody in 63 aspirates of peripheral lymph nodes sampled from patients suffering from non-Hodgkin's lymphoma. Referring to the dominant cell population in nodal aspirates, a rising trend of Ki-67 proliferative marker was noted from the small cells (X = 13.20) and small cells with notched nucleus (X = 43.52) and large cells (X = 79.47) with histopathologic equivalents corresponding to aggressive lymphoma. Statistical testing of the difference in the Ki-67 proliferative marker against demographic and clinical-laboratory characteristics of the studied patients revealed the levels of significance for the performance status, bone marrow infiltration, and albumin serum value. Correlation of cytomorphological and immunocytochemical results was tested against International Prognostic Index (IPI). Statistically significant correlation of Ki-67 with cytomorphology and REAL-immunocytochemical classification of lymphoma was confirmed, but not with the IPI index. In order to determine the prognostic importance of Ki-67 marker, the patients were classified into those with low Ki-67 (<20% of proliferating cells), mean proliferation index Ki-67 (range 20-59%), and high proliferative index Ki-67 (positive in over 60% of lymphoma cells). Testing Ki-67 with survival we have found that the low proliferative index was associated with the longest survival, median about 36 mo; for proliferative marker values ranging between 20 and 59%, the median survival was 30.4 mo; and survival of patients with the high proliferative index was only 12.9 mo.

Background:Vitamin D was investigated as a prective factor in lymphoid malignancies recently.Aims:Assessment of 25(OH) vitamin D status in lymphoid malignacies before active treatment and its influence on event‐free survival (EFS).Methods:Study included 153 patients, median age 58(18‐84) years with diagnose: diffuse large B cell lymphoma‐70, Hodgkin lymphoma‐22, chronic lymphocitic leukemia‐21, follicular lymphoma‐20 and multiple myeloma‐20, who had pretreatment 25(OH) vitamin D level. Comorbidities were assessed by Cumulative comorbidity index (CIRS). Patients were treated with immunochemotherapy and followed for event‐free survival for median 38(2‐53) months.Event was defined as progression or death.Results:Pretreatment serum 25(OH) vitamin D was 34,4 ± 13,6 nmol/l, without significant difference between lymphoma subgroups (ANOVA p = 0,069). Multivariate Cox regression for EFS showed 25(OH)D<25nmol/l (HR 2,732, 95%CI 1,37‐5,44), elevated LDH (HR 3,79, 95%CI 1,87‐7,66) and CIRS > 3 (HR 2,88, 95%CI 1,43‐5,78) as significant parameters for EFS.Summary/Conclusion:Average pretreatment 25(OH)D level in lymphoid malignancies is low. Severe deficiency, 25(OH)D <25nmol/l, is strong predictor of EFS in analysed group of patients.

No abstract

No abstract